• Acquisition funding: Sun Pharma plans to finance the Organon deal using $2 to $2.5 billion from its $3.1 billion cash surplus and $9.25 to $9.75 billion via external borrowing, potentially swapping existing debt with bondholders. The combined entities generate approximately $2.5 billion in pro forma cash flow, which management expects will support disciplined debt deleveraging.
• Synergy realization: Projected cost synergies of roughly $350 million are expected to kick in over years 2 to 4, as year 1 will absorb transaction and integration costs. Concrete plans and timelines for sales synergies will be finalized over the 6 to 9 months leading up to the transaction close.
• Portfolio growth outlook: Innovative products are projected to be the primary double-digit growth driver, while biosimilars—currently growing at 13%—will leverage Organon's global platform ahead of $350 billion worth of biologics going off-patent by 2035. The established products segment, representing 50% to 51% of the business, will focus on line extensions and new formulations to reverse flat growth.
• US tariff exposure: Management expects recent US tariff announcements to have a limited impact on the company's overall bottom line, noting that plans are in place to manage exposure on specialty assets such as Ilumya.